Upadacitinib is an oral JAK1 inhibitor approved for the treatment of psoriatic arthritis. It was a pleasure to talk with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) about the impact of axial involvement on patients with psoriatic arthritis and the findings from his study investigating upadacitinib in the treatment of PsA with axial involvement.
The abstract ‘EFFICACY OF UPADACITINIB ON PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT DEFINED BY INVESTIGATOR ASSESSMENT AND PROBASED CRITERIA: RESULTS FROM TWO PHASE 3 STUDIES.’ (Abstract number: POS0934) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
- What is the impact of axial involvement on patients with psoriatic arthritis (PsA)? (0:19)
- How is axial involvement identified in patients with PsA? (1:17)
- What was the rationale for, and design of, the post-hoc analysis you are presenting? (2:23)
- What were the findings of this analysis, and how do they compare with previous data? (3:13)
- What are the clinical implications of these findings? (4:31)
Disclosures: Xenofon Baraliakos discloses consulting for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving payment or honoraria for lectures from: Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving grant/ research support from Abbvie, Novartis and MSD; serving on advisory boards for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving honoraria from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; participating in speaker’s bureaus for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
Share this Video
Related Videos In Psoriatic Arthritis
Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in evaluating symptoms of axial involvement in psoriatic arthritis
In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial involvement in psoriatic arthritis. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, […]
Laure Gossec, ACR 2022: Guselkumab efficacy in psoriatic arthritis assessed by multi-domain composite indices
The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing efficacy of guselkumab by multi-domain composite indices. This information is brought to you by Touch […]
Laure Gossec, EULAR 2022: Guselkumab for Psoriatic Arthritis – An Analysis of the Phase 3b COSMOS Trial
The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!